<?xml version="1.0" encoding="UTF-8"?>
<drug type="small molecule" created="2007-11-18" updated="2019-12-02">
  <drugbank-id primary="true">DB05874</drugbank-id>
  <name>AEOL 10150</name>
  <description>AEOL 10150 is developed by Aeolus as a therapeutic agents based on its proprietary small molecule catalytic antioxidants. </description>
  <cas-number/>
  <unii>KPKO7W46E8</unii>
  <state>solid</state>
  <groups>
    <group>investigational</group>
  </groups>
  <general-references>
    <articles>
      <article>
        <ref-id>A3871</ref-id>
        <pubmed-id>17957541</pubmed-id>
        <citation>Rabbani ZN, Salahuddin FK, Yarmolenko P, Batinic-Haberle I, Thrasher BA, Gauter-Fleckenstein B, Dewhirst MW, Anscher MS, Vujaskovic Z: Low molecular weight catalytic metalloporphyrin antioxidant AEOL 10150 protects lungs from fractionated radiation. Free Radic Res. 2007 Nov;41(11):1273-82.</citation>
      </article>
      <article>
        <ref-id>A3872</ref-id>
        <pubmed-id>12374626</pubmed-id>
        <citation>Bowler RP, Sheng H, Enghild JJ, Pearlstein RD, Warner DS, Crapo JD: A catalytic antioxidant (AEOL 10150) attenuates expression of inflammatory genes in stroke. Free Radic Biol Med. 2002 Oct 15;33(8):1141-52.</citation>
      </article>
    </articles>
    <textbooks/>
    <links/>
    <attachments/>
  </general-references>
  <synthesis-reference/>
  <indication>Investigated for use/treatment in amyotrophic lateral sclerosis (ALS).</indication>
  <pharmacodynamics/>
  <mechanism-of-action>AEOL 10150 shows the ability to scavenge a broad range of reactive oxygen species, or free radicals. As a catalytic antioxidant, AEOL 10150 mimics and thereby amplifies the body's natural enzymatic systems for eliminating these damaging compounds. Because oxygen-derived free radicals are believed to have an important role in the pathogenesis of many diseases, aeolus' catalytic antioxidants are believed to have a broad range of potential therapeutic uses.</mechanism-of-action>
  <toxicity/>
  <metabolism/>
  <absorption/>
  <half-life/>
  <protein-binding/>
  <route-of-elimination/>
  <volume-of-distribution/>
  <clearance/>
  <salts/>
  <synonyms/>
  <products/>
  <international-brands/>
  <mixtures/>
  <packagers/>
  <manufacturers/>
  <prices/>
  <categories>
    <category>
      <category>Antioxidants</category>
      <mesh-id>D000975</mesh-id>
    </category>
    <category>
      <category>Biological Factors</category>
      <mesh-id>D001685</mesh-id>
    </category>
    <category>
      <category>Heterocyclic Compounds, Fused-Ring</category>
      <mesh-id>D000072471</mesh-id>
    </category>
    <category>
      <category>Pigments, Biological</category>
      <mesh-id>D010860</mesh-id>
    </category>
    <category>
      <category>Porphyrins</category>
      <mesh-id>D011166</mesh-id>
    </category>
  </categories>
  <affected-organisms/>
  <dosages/>
  <atc-codes/>
  <ahfs-codes/>
  <pdb-entries/>
  <patents/>
  <food-interactions/>
  <drug-interactions/>
  <calculated-properties/>
  <experimental-properties/>
  <external-identifiers>
    <external-identifier>
      <resource>PubChem Substance</resource>
      <identifier>347910284</identifier>
    </external-identifier>
  </external-identifiers>
  <external-links/>
  <pathways/>
  <reactions/>
  <snp-effects/>
  <snp-adverse-drug-reactions/>
  <targets/>
  <enzymes/>
  <carriers/>
  <transporters/>
</drug>